Ausgabe 9/2009
Inhalt (22 Artikel)
Commentary on: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients
Isabelle Brenot-Rossi, Cyrille Bastide
Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients
G. Holl, R. Dorn, H. Wengenmair, D. Weckermann, J. Sciuk
Comparison of a 1-day and a 2-day protocol for lymphatic mapping and sentinel lymph node biopsy in patients with nonpalpable breast cancer
S. van Esser, M. Hobbelink, J. W. Van Isselt, W. P. Th. M. Mali, I. H. M. Borel Rinkes, R. van Hillegersberg
Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT
Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Domeki, Masahiro Tsubaki, Masakatsu Sunagawa, Yasushi Kaji, Narufumi Suganuma, Kazuro Sugimura
Incidental head and neck 18F-FDG uptake on PET/CT without corresponding morphological lesion: early predictor of cancer development?
Till A. Heusner, Steffen Hahn, Monia E. Hamami, Svenja Kögel, Michael Forsting, Andreas Bockisch, Gerald Antoch, Alexander R. Stahl
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma
Mirco Bartolomei, Lisa Bodei, Concetta De Cicco, Chiara Maria Grana, Marta Cremonesi, Edoardo Botteri, Silvia Melania Baio, Demetrio Aricò, Maddalena Sansovini, Giovanni Paganelli
Staging primary head and neck cancers with 18F-FDG PET/CT: is intravenous contrast administration really necessary?
Keisuke Yoshida, Akiko Suzuki, Toshiyuki Nagashima, Jin Lee, Choichi Horiuchi, Mamoru Tsukuda, Tomio Inoue
188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study
Marnix G. E. H. Lam, Tjitske B. Bosma, Peter P. van Rijk, Bernard A. Zonnenberg
Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment
Sebastian A. Müller, Korbinian Holzapfel, Christof Seidl, Uwe Treiber, Bernd J. Krause, Reingard Senekowitsch-Schmidtke
In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
Flavio Forrer, Jianhua Chen, Melpomeni Fani, Pia Powell, Andreas Lohri, Jan Müller-Brand, Gerhard Moldenhauer, Helmut R. Maecke
[18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology
Örjan Lindhe, Aijun Sun, Johan Ulin, Obaidur Rahman, Bengt Långström, Jens Sörensen
The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy
Vladimir Tolmachev, Helena Wållberg, Karl Andersson, Anders Wennborg, Hans Lundqvist, Anna Orlova
18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK)
Christina Hultsch, Margret Schottelius, Jörg Auernheimer, Andrea Alke, Hans-Jürgen Wester
68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging
Zhaofei Liu, Gang Niu, Fan Wang, Xiaoyuan Chen
Targeting murine heart and brain: visualisation conditions for multi-pinhole SPECT with 99mTc- and 123I-labelled probes
M. Pissarek, J. Meyer-Kirchrath, T. Hohlfeld, S. Vollmar, A. M. Oros-Peusquens, U. Flögel, C. Jacoby, U. Krügel, N. Schramm
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab
Gang Niu, Zibo Li, Qizhen Cao, Xiaoyuan Chen
Monitoring cancer therapy with PET: probably effective, but more research is needed
Giovanni Lucignani
Eugene C. Lin, Edward J. Escott, Kavita D. Garg, Andrew G. Bleicher, David Alexander: Practical differential diagnosis for CT and MRI
Maurizio Sacco, Luigi Mansi
Focal fat mimicking multiple hepatic metastases on FDG PET/CT imaging
Maurice H. Zissen, Andrew Quon
EANM guidelines for ventilation/perfusion scintigraphy
M. Bajc, J. B. Neilly, M. Miniati, C. Schuemichen, M. Meignan, B. Jonson